Elicera Therapeutics AB (ST:ELIC) — Market Cap & Net Worth
Market Cap & Net Worth: Elicera Therapeutics AB (ELIC)
Elicera Therapeutics AB (ST:ELIC) has a market capitalization of $17.45 Million (Skr162.11 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #25440 globally and #524 in its home market, demonstrating a -0.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Elicera Therapeutics AB's stock price Skr3.34 by its total outstanding shares 48535544 (48.54 Million). Analyse Elicera Therapeutics AB cash conversion from operations to see how efficiently the company converts income to cash.
Elicera Therapeutics AB Market Cap History: 2021 to 2026
Elicera Therapeutics AB's market capitalization history from 2021 to 2026. Data shows change from $26.22 Million to $17.45 Million (-11.89% CAGR).
Index Memberships
Elicera Therapeutics AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.12% | #124 of 281 |
Weight: Elicera Therapeutics AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Elicera Therapeutics AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Elicera Therapeutics AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.22x
Elicera Therapeutics AB's market cap is 1.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $26.22 Million | $587.00 | -$13.12 Million | 44668.59x | N/A |
| 2022 | $18.36 Million | $1.28 Million | -$19.52 Million | 14.34x | N/A |
| 2023 | $23.82 Million | $11.23 Million | -$16.40 Million | 2.12x | N/A |
| 2024 | $8.72 Million | $7.13 Million | -$16.11 Million | 1.22x | N/A |
Competitor Companies of ELIC by Market Capitalization
Companies near Elicera Therapeutics AB in the global market cap rankings as of May 4, 2026.
Key companies related to Elicera Therapeutics AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Elicera Therapeutics AB Historical Marketcap From 2021 to 2026
Between 2021 and today, Elicera Therapeutics AB's market cap moved from $26.22 Million to $ 17.45 Million, with a yearly change of -11.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr17.45 Million | -36.02% |
| 2025 | Skr27.27 Million | +212.57% |
| 2024 | Skr8.72 Million | -63.38% |
| 2023 | Skr23.82 Million | +29.73% |
| 2022 | Skr18.36 Million | -29.98% |
| 2021 | Skr26.22 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Elicera Therapeutics AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.45 Million USD |
| MoneyControl | $17.45 Million USD |
| MarketWatch | $17.45 Million USD |
| marketcap.company | $17.45 Million USD |
| Reuters | $17.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing EL… Read more